eMedicine Specialties > Dermatology > Diseases of the Vessels

Erythema Induratum (Nodular Vasculitis)

Author: Noah S Scheinfeld, MD, JD, FAAD, Assistant Clinical Professor, Department of Dermatology, Columbia University; Consulting Staff, Department of Dermatology, St Luke's Roosevelt Hospital Center, Beth Israel Medical Center, New York Eye and Ear Infirmary; Private Practice
Contributor Information and Disclosures

Updated: Jan 7, 2010

Introduction

Background

In 1861, Bazin gave the name erythema induratum to a nodular eruption that occurred on the lower legs of young women with tuberculosis. In 1945, Montgomery et al, while fully acknowledging the existence of tuberculosis-associated erythema induratum, coined the term nodular vasculitis to describe chronic inflammatory nodules of the legs that showed histopathologic changes similar to those of erythema induratum, that is, vasculitis of the larger vessels and panniculitis.

Erythema induratum and nodular vasculitis had been considered the same disease entity for a long time. However, nodular vasculitis is now considered a multifactorial syndrome of lobular panniculitis in which tuberculosis may or may not be one of a multitude of etiologic components. Therefore, erythema induratum/nodular vasculitis complex is classified into 2 variants: erythema induratum of Bazin type and nodular vasculitis or erythema induratum of Whitfield type. The Bazin type is related with tuberculous origin, but Whitfield type is not.

One report describes erythema induratum of 3 years’ duration caused by chronic hepatitis C infection in a 49-year-old man. The erythema induratum responded to pegylated interferon and ribavirin therapy for 48 weeks.1

Motswaledi and Schulz2 noted that erythema induratum of Bazin, lichen scrofulosorum, and papulonecrotic tuberculide are the 3 recognized tuberculides, which are sequelae of immunologic reactions to hematogenously dispersed antigenic components of Mycobacterium tuberculosis. A fourth tuberculide, called nodular granulomatous phlebitis, is distinct from erythema induratum.

Related eMedicine articles include Tuberculosis (emergency medicine focus), Tuberculosis (infectious disease focus), Tuberculosis (ophthalmology focus), and Tuberculosis (pediatric focus).

Pathophysiology

The morphologic, molecular, and clinical data suggest that erythema induratum and nodular vasculitis represent a common inflammatory pathway, that is, a hypersensitivity reaction to endogenous or exogenous antigens. One such antigen is the tubercle bacillus. Patients with erythema induratum have a positive tuberculin skin test result and a marked increase in their peripheral T lymphocyte response to purified protein derivative (PPD) of tuberculin, which can cause a delayed-type hypersensitivity reaction. Results from the enzyme-linked immunosorbent assay–based IGRA (QuantiFERON-TB Gold In-Tube, Cellestis; Victoria, Australia) blood test for tuberculosis commonly are positive in patients with erythema induratum, again suggesting that that erythema induratum is a hypersensitivity reaction to a systemic infection.

Frequency

United States

Isolated cases of erythema induratum have been reported in the United States.

International

While nodular vasculitis is quite common, particularly in Europe, erythema induratum is rare in Western countries. Erythema induratum is still prevalent in India, Hong Kong, and some areas of South Africa. Erythema induratum was the most common (86%) form of cutaneous tuberculosis (tuberculid) in Hong Kong found between 1993 and 20023 and was mostly found in women and mostly on the legs. In this period (1993-2002), 127 patients with erythema induratum out of a total of 147 patients with either cutaneous tuberculosis or tuberculids were reported.

Mortality/Morbidity

To date, no fatal cases of erythema induratum have been reported. However, the chronic, recurrent, painful nodules and resultant scarring can be a source of significant morbidity.

Sex

Erythema induratum shows female predominance, and lower extremities are the most common sites in both male and female patients; however, it also may occur in other areas.

Age

Erythema induratum most commonly affects women aged 20-30 years. The condition is more common in young women than in other people, but it may occur later in life.

Clinical

History

  • A past or present history of tuberculosis at an extracutaneous site occurs in about 50% of patients.
    • Pulmonary tuberculosis is most common.
    • Tuberculous cervical lymphadenitis is the next most common finding.
  • Tender, erythematous nodules are present on the lower legs.
    • The nodules have a chronic, recurrent course.
    • The lesions heal with ulcerations or depressed scars.
  • Leg edema may be present.
  • An infant erythema induratum was reported to occur after BCG vaccination.4
  • The simultaneous expression of erythema induratum and episcleritis was reported in a 6-year-old girl.5
  • A variation of erythema induratum, termed nodular tuberculid, with the distinguishing feature of a granulomatous vasculitis occurring at the dermohypodermal junction, has been noted in 5 patients with HIV disease.6
  • Erythema induratum of Bazin and renal tuberculosis can be associated.7
  • Silva et al8 noted distal painful peripheral neuropathy associated with erythema induratum.

Physical

  • Crops of small, tender, erythematous nodules may be observed, as demonstrated in the image below.

  • This patient exhibited tender, erythematous nodul...

    This patient exhibited tender, erythematous nodules confined to the lower third of the legs.

    This patient exhibited tender, erythematous nodul...

    This patient exhibited tender, erythematous nodules confined to the lower third of the legs.


    • Commons sites are the calves, although the shins are also sometimes involved. Uncommonly, the trunk, buttocks, thighs, and arms can be involved.
    • The nodules are concentrated on the lower third of the legs, especially around the ankles.
    • Lesions may ulcerate with bluish borders, which may be precipitated by cold weather. These irregular and shallow ulceration can result in permanent scarring and hyperpigmentation of the lesions.
    • In 2007, Ramdial et al9 reported on 5 patients with tuberculous epididymo-orchitis. A histopathological evaluation confirmed papulonecrotic tuberculids in 4 patients and erythema induratum in 2 patients. Most patients responded to appropriate antibiotics. The researchers concluded that tuberculids incite a sentinel cutaneous manifestation of visceral tuberculosis and help identify occult or asymptomatic tuberculous epididymo-orchitis, as the underlying cause of tuberculids.
    • Sughimoto et al10 described a patient with aortic valvular lesions of tuberculosis that manifest at the same time as erythema induratum, with granulomatous changes being demonstrated by the aortic valve pathology.

Causes

Erythema induratum/nodular vasculitis complex is a multifactorial disorder. M tuberculosis and delayed-type hypersensitivity are considered etiologic factors for erythema induratum of Bazin type. Recently, hepatitis C virus has been suggested, but a direct relationship remains unclear.

  • M tuberculosis is the cause of erythema induratum.
  • The cause is unknown in cases of nodular vasculitis with a negative tuberculin skin test reaction.
  • Atypical erythema induratum Bazin with tuberculous osteomyelitis has been reported, suggesting that boney changes can be detected clinically.11

More on Erythema Induratum (Nodular Vasculitis)

Overview: Erythema Induratum (Nodular Vasculitis)
Differential Diagnoses & Workup: Erythema Induratum (Nodular Vasculitis)
Treatment & Medication: Erythema Induratum (Nodular Vasculitis)
Follow-up: Erythema Induratum (Nodular Vasculitis)
Multimedia: Erythema Induratum (Nodular Vasculitis)
References

References

  1. Fernandes SS, Carvalho J, Leite S, et al. Erythema induratum and chronic hepatitis C infection. J Clin Virol. Apr 2009;44(4):333-6. [Medline].

  2. Motswaledi HM, Schulz EJ. Superficial thrombophlebitic tuberculide. Int J Dermatol. Nov 2006;45(11):1337-40. [Medline].

  3. Ho CK, Ho MH, Chong LY. Cutaneous tuberculosis in Hong Kong: an update. Hong Kong Med J. Aug 2006;12(4):272-7. [Medline].

  4. Inoue T, Fukumoto T, Ansai S, Kimura T. Erythema induratum of Bazin in an infant after Bacille Calmette-Guerin vaccination. J Dermatol. Apr 2006;33(4):268-72. [Medline].

  5. Leahy TR, Downey P, Ramsay B, Philip RK. Erythema induratum of Bazin and episcleritis in a 6 year old girl. Arch Dis Child. Nov 2005;90(11):1132. [Medline].

  6. Friedman PC, Husain S, Grossman ME. Nodular tuberculid in a patient with HIV. J Am Acad Dermatol. Aug 2005;53(2 Suppl 1):S154-6. [Medline].

  7. Daher Ede F, Silva Junior GB, Pinheiro HC, Oliveira TR, Vilar Mdo L, Alcantara KJ. Erythema induratum of Bazin and renal tuberculosis: report of an association. Rev Inst Med Trop Sao Paulo. Sep-Oct 2004;46(5):295-8. [Medline].

  8. Silva MT, Antunes SL, Rolla VC, Galhardo MC, Sant'ana FM, do Valle AF. Distal painful peripheral neuropathy associated with erythema induratum of Bazin. Eur J Neurol. Dec 2006;13(12):e5-6. [Medline].

  9. Ramdial PK, Calonje E, Sydney C, Subrayen S, Meyiwa PS, Aboobaker J. Tuberculids as sentinel lesions of tuberculous epididymo-orchitis. J Cutan Pathol. Nov 2007;34(11):830-6. [Medline].

  10. Sughimoto K, Nakano K, Gomi A, et al. Aortic valve stenosis associated with Bazin's disease. J Heart Valve Dis. Mar 2007;16(2):212-3. [Medline].

  11. Degonda Halter M, Nebiker P, Hug B, Oberholzer M, Fluckiger U, Bassetti S. [Atypical erythema induratum Bazin with tuberculous osteomyelitis]. Internist (Berl). Aug 2006;47(8):853-6. [Medline].

  12. Jacinto SS, Nograles KB. Erythema induratum of bazin: role of polymerase chain reaction in diagnosis. Int J Dermatol. May 2003;42(5):380-1. [Medline].

  13. Chen YH, Yan JJ, Chao SC, Lee JY. Erythema induratum: a clinicopathologic and polymerase chain reaction study. J Formos Med Assoc. Apr 2001;100(4):244-9. [Medline].

  14. Schneider JW, Jordaan HF, Geiger DH, Victor T, Van Helden PD, Rossouw DJ. Erythema induratum of Bazin. A clinicopathological study of 20 cases and detection of Mycobacterium tuberculosis DNA in skin lesions by polymerase chain reaction. Am J Dermatopathol. Aug 1995;17(4):350-6. [Medline].

  15. Angus J, Roberts C, Kulkarni K, Leach I, Murphy R. Usefulness of the QuantiFERON test in the confirmation of latent tuberculosis in association with erythema induratum. Br J Dermatol. Dec 2007;157(6):1293-4. [Medline].

  16. Segura S, Pujol RM, Trindade F, Requena L. Vasculitis in erythema induratum of Bazin: a histopathologic study of 101 biopsy specimens from 86 patients. J Am Acad Dermatol. Nov 2008;59(5):839-51. [Medline].

  17. Alothman A, Al Qahtani M, Al-Khenaizan S. Erythema induratum: what is the role of Mycobacterium tuberculosis?. Ann Saudi Med. Jul-Aug 2007;27(4):298-300. [Medline].

  18. Baselga E, Margall N, Barnadas MA, Coll P, de Moragas JM. Detection of Mycobacterium tuberculosis DNA in lobular granulomatous panniculitis (erythema induratum-nodular vasculitis). Arch Dermatol. Apr 1997;133(4):457-62. [Medline].

  19. Bennett NM. Erythema induratum: a case of mistaken identity. Med J Aust. Mar 20 2006;184(6):306; author reply 306-7. [Medline].

  20. Chanet V, Amarger S, Pons B, Déchelotte P, Ruivard M, Philippe P. [Nodular thrombophlebitis and granulomatous systemic disease]. Rev Med Interne. Jun 2007;28(6):416-9. [Medline].

  21. Cho KH, Lee DY, Kim CW. Erythema induratum of Bazin. Int J Dermatol. Nov 1996;35(11):802-8. [Medline].

  22. Hay RJ. Cutaneous infection with Mycobacterium tuberculosis: how has this altered with the changing epidemiology of tuberculosis?. Curr Opin Infect Dis. Apr 2005;18(2):93-5. [Medline].

  23. Heymann WR. Panniculitis. J Am Acad Dermatol. Apr 2005;52(4):683-5. [Medline].

  24. Koga T, Kubota Y, Kiryu H, Nakayama J, Matsuzoe D, Shirakusa T. Erythema induratum in a patient with active tuberculosis of the axillary lymph node: IFN-gamma release of specific T cells. Eur J Dermatol. Jan-Feb 2001;11(1):48-9. [Medline].

  25. Mascaro JM Jr, Baselga E. Erythema induratum of bazin. Dermatol Clin. Oct 2008;26(4):439-45, v. [Medline].

  26. Requena L. Normal subcutaneous fat, necrosis of adipocytes and classification of the panniculitides. Semin Cutan Med Surg. Jun 2007;26(2):66-70. [Medline].

  27. Schneider JW, Jordaan HF. The histopathologic spectrum of erythema induratum of Bazin. Am J Dermatopathol. Aug 1997;19(4):323-33. [Medline].

  28. White WL. On Japanese baseball and erythema induratum of Bazin. Am J Dermatopathol. Aug 1997;19(4):318-22. [Medline].

  29. Wiebels D, Turnbull K, Steinkraus V, Böer A. [Erythema induratum Bazin. "Tuberculid" or tuberculosis?]. Hautarzt. Mar 2007;58(3):237-40. [Medline].

Further Reading

Keywords

erythema induratum, nodular vasculitis, tuberculosis-associated erythema induratum, TB-associated erythema induratum, erythema induratum of Bazin

Contributor Information and Disclosures

Author

Noah S Scheinfeld, MD, JD, FAAD, Assistant Clinical Professor, Department of Dermatology, Columbia University; Consulting Staff, Department of Dermatology, St Luke's Roosevelt Hospital Center, Beth Israel Medical Center, New York Eye and Ear Infirmary; Private Practice
Noah S Scheinfeld, MD, JD, FAAD is a member of the following medical societies: American Academy of Dermatology
Disclosure: Optigenex Consulting fee Independent contractor

Medical Editor

Jean-Hilaire Saurat, MD, Chair, Professor, Department of Dermatology, University of Geneva, Switzerland
Jean-Hilaire Saurat, MD is a member of the following medical societies: American Academy of Dermatology, American Dermatological Association, and Society for Investigative Dermatology
Disclosure: Nothing to disclose.

Pharmacy Editor

Richard P Vinson, MD, Assistant Clinical Professor, Department of Dermatology, Texas Tech University School of Medicine; Consulting Staff, Mountain View Dermatology, PA
Richard P Vinson, MD is a member of the following medical societies: American Academy of Dermatology, Association of Military Dermatologists, Texas Dermatological Society, and Texas Medical Association
Disclosure: Nothing to disclose.

Managing Editor

Lester F Libow, MD, Dermatopathologist, South Texas Dermatopathology Laboratory
Lester F Libow, MD is a member of the following medical societies: American Academy of Dermatology, American Society of Dermatopathology, and Texas Medical Association
Disclosure: Nothing to disclose.

CME Editor

Joel M Gelfand, MD, MSCE, Medical Director, Clinical Studies Unit, Assistant Professor, Department of Dermatology, Associate Scholar, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania
Joel M Gelfand, MD, MSCE is a member of the following medical societies: Society for Investigative Dermatology
Disclosure: AMGEN Consulting fee Consulting; AMGEN Grant/research funds Investigator; Genentech Grant/research funds investigator; Centocor Consulting fee Consulting; Abbott Grant/research funds investigator; Abbott Consulting fee Consulting; Novartis  investigator; Pfizer Grant/research funds investigator; Celgene Consulting fee DMC Chair; NIAMS and NHLBI Grant/research funds investigator

Chief Editor

Dirk M Elston, MD, Director, Department of Dermatology, Geisinger Medical Center
Dirk M Elston, MD is a member of the following medical societies: American Academy of Dermatology
Disclosure: Nothing to disclose.

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.